This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Chart e-therapeutics plc
More charts
e-therapeutics plc is a United Kingdom-based company engaged in integrating computational power and biological data to discover life-transforming RNA interference (RNAi) medicines. The Company's technology uses computation to capture and model human biology, identify targets, and develop RNAi medicines against those targets that can be progressed to the clinic. Its HepNet platform enables the generation and analysis of biological network models, providing a mechanistic approach to drug discovery. Its RNAi platform, GalOmic, enables targeted delivery to hepatocytes in the liver and the specific silencing of disease-associated genes, identified by HepNet. The Company is progressing a pipeline of RNAi candidates across a variety of therapeutic areas with high unmet need, including preclinical programs in cardiometabolic and metabolic diseases, hemophilia, and other undisclosed indications. Its pipeline includes ETX-312, ETX-407, ETX-148, ETX-291 and others.
More about the company
  1. Stock Market
  2. Equities
  3. ETXPF Stock
  4. ETX Stock
  5. News e-therapeutics plc
  6. UK's e-therapeutics plc to Raise GBP29 Million from M&G, Investor
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW